Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reshma Kewalramani
Pharma
Vertex narrows development plan for non-opioid pain med Journavx
Vertex is narrowing development plans for Journavx and will specifically pursue a nod in diabetic peripheral neuropathy.
Fraiser Kansteiner
Aug 5, 2025 10:55am
The 10 highest-paid Big Pharma CEOs of 2024
Jun 16, 2025 3:00am
Vertex raises pay of CEO Reshma Kewalramani by 4% to $21.5M
Apr 9, 2025 5:45am
The top 10 best-paid CEOs in Big Pharma in 2023
Jun 17, 2024 3:00am
Reshma Kewalramani joins exclusive club, topping $20M in pay
Apr 8, 2024 8:26am
Don't pigeonhole Vertex as a rare disease company, execs say
May 6, 2022 7:55am
